Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Armata Pharmaceuticals, Inc. ARMP

Healthcare  —  Biotechnology
3.74 0.12 3.31% as of 25 Sep
Market cap
$136.5M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Armata Pharmaceuticals, Inc. (ARMP) Business Profile

Updated before January 2025

Company Overview

Armata Pharmaceuticals, Inc. (NASDAQ: ARMP) is a biotechnology company specializing in the development of precision bacteriophage therapeutics for the treatment of antibiotic-resistant bacterial infections. Founded in 2019 through the merger of AmpliPhi Biosciences Corporation and C3J Therapeutics, Armata is headquartered in Marina del Rey, California. The company is led by a team of seasoned professionals with extensive experience in biotechnology and pharmaceuticals. Key leadership includes Dr. Brian Varnum, President and CEO, who brings decades of expertise in drug development and commercialization, and Todd R. Patrick, Chairman of the Board, who has a strong background in corporate strategy and governance.

Core Business Segments

Armata Pharmaceuticals focuses on the development of bacteriophage-based therapies, which are viruses that specifically target and kill bacteria. The company’s core business segments include:

1. Therapeutic Development

Armata’s primary focus is on developing bacteriophage therapies to combat multidrug-resistant bacterial infections. Key products in this segment include:

  • AP-SA02: A bacteriophage therapy targeting Staphylococcus aureus infections, including methicillin-resistant Staphylococcus aureus (MRSA).
  • AP-PA02: A bacteriophage therapy designed to treat Pseudomonas aeruginosa infections, a common cause of hospital-acquired infections.

2. Research and Development (R&D)

Armata invests heavily in R&D to expand its bacteriophage platform. The company collaborates with academic institutions, government agencies, and private organizations to advance its pipeline of therapies targeting other bacterial pathogens.

3. Clinical Trials

Armata conducts clinical trials to evaluate the safety and efficacy of its bacteriophage therapies. The company is currently in various stages of clinical development for its lead candidates, AP-SA02 and AP-PA02.

Business Model

Armata Pharmaceuticals operates on a business model centered around innovation, collaboration, and commercialization. The company generates revenue through:

  • Grants and Partnerships: Armata collaborates with government agencies, such as the National Institutes of Health (NIH), and private organizations to secure funding for its R&D efforts.
  • Licensing Agreements: The company licenses its bacteriophage technology to other pharmaceutical companies for commercialization.
  • Product Sales: Once its therapies receive regulatory approval, Armata plans to generate revenue through the sale of its bacteriophage-based products.

Strategic Direction

Armata Pharmaceuticals is committed to addressing the global health crisis posed by antibiotic-resistant infections. The company’s strategic priorities include:

  • Pipeline Expansion: Developing new bacteriophage therapies targeting additional bacterial pathogens.
  • Regulatory Approvals: Advancing its lead candidates, AP-SA02 and AP-PA02, through clinical trials to secure regulatory approvals.
  • Global Partnerships: Strengthening collaborations with academic institutions, government agencies, and pharmaceutical companies to accelerate the development and commercialization of its therapies.
  • Sustainability Goals: Promoting sustainable healthcare solutions by reducing reliance on traditional antibiotics and minimizing the environmental impact of its operations.

Competitive Landscape

Armata Pharmaceuticals operates in a highly competitive biotechnology sector. Key competitors include:

  • Adaptive Phage Therapeutics: A company focused on developing personalized bacteriophage therapies.
  • Phagomed Biopharma: Specializes in phage-based treatments for bacterial infections.
  • ContraFect Corporation: Develops lysins and other biologics to combat antibiotic-resistant infections.
  • Big Pharma Companies: Large pharmaceutical companies like Pfizer and Merck are also investing in alternative therapies for bacterial infections.

Risk Factors

Armata Pharmaceuticals faces several risks, including:

  • Regulatory Challenges: The approval process for bacteriophage therapies is complex and time-consuming.
  • Market Dependence: The company’s success depends on the commercial viability of its lead candidates.
  • Supply Chain Disruptions: Delays in the production and distribution of bacteriophage therapies could impact operations.
  • Competition: The biotechnology sector is highly competitive, with numerous companies developing alternative therapies.
  • Financial Risks: As a clinical-stage company, Armata relies on external funding and may face financial constraints if it fails to secure additional capital.

Recent Developments

  • Clinical Trial Progress: Armata recently announced positive interim results from its Phase 1b/2a clinical trial for AP-PA02, demonstrating safety and preliminary efficacy in treating Pseudomonas aeruginosa infections.
  • Partnerships: The company entered into a collaboration with the U.S. Department of Defense to develop bacteriophage therapies for military personnel.
  • Funding: Armata secured additional funding from Innoviva, Inc., its largest shareholder, to support ongoing R&D efforts.
  • Global Developments: The COVID-19 pandemic highlighted the importance of addressing antimicrobial resistance, increasing interest in bacteriophage therapies.

Investment Considerations

Strengths

  • Innovative Technology: Armata is a leader in bacteriophage-based therapies, a promising alternative to traditional antibiotics.
  • Strong Pipeline: The company has a robust pipeline of candidates targeting high-priority bacterial pathogens.
  • Collaborative Approach: Partnerships with government agencies and academic institutions provide access to funding and expertise.

Risks

  • Clinical and Regulatory Uncertainty: The success of Armata’s therapies depends on positive clinical trial results and regulatory approvals.
  • Financial Dependence: The company relies on external funding and may face challenges in securing additional capital.
  • Market Competition: Armata competes with both established pharmaceutical companies and emerging biotech firms.

Conclusion

Armata Pharmaceuticals is at the forefront of developing innovative bacteriophage therapies to combat antibiotic-resistant infections. With a strong pipeline, strategic partnerships, and a commitment to addressing global health challenges, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical-stage biotechnology companies, including regulatory and financial uncertainties. Overall, Armata represents a promising investment opportunity in the rapidly evolving field of precision medicine.